Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Portable Absence Seizure Detection Using Smart Earbuds (PAUSE)

12 november 2026 bijgewerkt door: Universitaire Ziekenhuizen KU Leuven

Typical absence seizures are the hallmark of idiopathic generalized epilepsy syndromes (CAE, JAE, JME) but are frequently underreported in patient diaries. Clinical studies have shown that 74% to 94% of absence seizures go unreported by patients or caregivers. While 24-hour video-EEG (vEEG) is the gold standard for quantification, it is expensive, hospital-based, and lacks the temporal resolution required for long-term management.

Previous studies successfully validated a wearable EEG (wEEG) solution using a behind-the-ear (BTE) form factor (Byteflies Sensor Dot). In the pilot study, the authors demonstrated that a reduced electrode configuration combined with ML algorithms could detect absence seizures with 98% sensitivity in the hospital setting and enable effective home-based treatment monitoring.

To expand the applicability of this method, validation of additional form factors is required. This study aims to extend our validation framework to a novel wEEG device that utilizes an ear configuration (earEEG).

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Gedetailleerde beschrijving

  1. Background, rationale and risk assessment

    1.1 Disease Background Typical absence seizures are the clinical hallmark of idiopathic generalized epilepsy syndromes, specifically Childhood Absence Epilepsy (CAE), Juvenile Absence Epilepsy (JAE), and Juvenile Myoclonic Epilepsy (JME)(1). These syndromes account for up to 20% of all people living with epilepsy, primarily affecting children, adolescents, and young adults(2). Clinically, absences are characterized by a transient loss of consciousness accompanied by generalized 3 Hz (2.5-5.5 Hz) spike-and-wave discharges (SWD) on the electroencephalogram (EEG). These seizures can have significant cognitive, affective, and behavioral comorbidities, particularly when not adequately controlled(1,3-5).

    1.2 Limitations of the Current Standard of Care Accurate quantification of the seizure burden is essential for optimizing the treatment with anti-seizure medications (ASM). The current standard of care relies on seizure diaries. However, previous studies indicate that the sensitivity of self-reporting for absence seizures ranges from 6% to 26% compared with video-EEG(6,7). i.e., seizure diaries have low reliability.

    Therefore, patients are intermittently followed with a 24-hour video electroencephalogram (vEEG), which has, among other limitations, high costs (approximately €1,200 per session in Belgium), long waiting times, and limited ecological validity, as they provide only a snapshot of the patient's condition that may not capture cyclical seizure variability(8).

    This study seeks to validate an objective, automated counting method using a wearable EEG (wEEG) device, first in a hospital setting and then at home.

    1.3 Rationale for Wearable EEG wEEG devices offer a promising alternative to full-scalp vEEG for long-term monitoring. By using a limited number of electrodes combined with Machine Learning (ML) algorithms, wEEG can enable intermittent or continuous, objective seizure counting outside the hospital.

    Researchers from ESAT-STADIUS & UZ Leuven have previously validated this approach using a behind-the-ear (BTE) wEEG device (The Sensor Dot, Byteflies, Antwerpen, Belgium). In a pilot study, an ML algorithm developed by the group achieved 98% sensitivity for detecting absence seizures in a hospital setting compared to standard EEG(6). Furthermore, a subsequent home-based pilot demonstrated the feasibility of using this system for treatment optimization(9).

    1.4 Justification for the Current Investigation While the BTE form factor has been validated, it may not be the optimal solution for all patients due to cosmetic concerns, comfort, or lifestyle constraints. To facilitate widespread adoption and personalized care, it is necessary to validate alternative wEEG form factors, such as earEEG.

    The device under investigation in this study, the NeuroBuds™, uses a novel ear electrode configuration that lacks rigorous clinical validation against the gold standard for absence seizure detection.

    Therefore, the primary purpose of this study is to validate the signal quality and diagnostic accuracy of the ESAT-STADIUS ML algorithms on the signals recorded with the Neurobuds against simultaneous standard vEEG. This validation is a prerequisite for developing a device-agnostic ML algorithm capable of processing data from various manufacturers and electrode montages.

    1.5 Benefit/Risk Assessment The IMD is CE-marked, non-invasive, and poses minimal risk to participants, comparable to that of standard scalp EEG electrodes. The potential risks are limited to mild skin irritation or discomfort at the electrode sites. The potential benefit is the validation of a less invasive monitoring alternative. Successful validation may allow for future home-based seizure quantification.

  2. Investigation objectives & design

2.1 Investigation objectives

Primary Objective The primary objective of this investigation is to validate the diagnostic accuracy of an investigational ear wEEG device, namely the NeuroBuds (Cebreo Medical), and an ML algorithm in detecting typical absence seizures. Specifically, the study aims to determine the sensitivity, precision, F1-score, and the FAR/24h of the ML seizure detection algorithm applied to signals recorded by the IMD, compared with simultaneous gold-standard video-EEG (vEEG) annotated by a neurologist.

Secondary Objectives

  1. Signal Quality: To assess the signal quality and artifact susceptibility of novel electrode form factors (earEEG) compared to standard wet scalp electrodes.
  2. Usability and Comfort: To evaluate patient and caregiver acceptance, comfort, and ease of use of the IMD in both hospital and home environments.
  3. Home Validation: To demonstrate the robustness of the data collection pipeline and algorithm performance in a real-world home environment, distinct from the controlled hospital setting.

Hypothesis In the hospital setting, the ML algorithm will achieve seizure-detection sensitivity of ≥90% (relative to simultaneous neurologist-annotated vEEG) after analyzing the data obtained with the IMD. These results should be comparable to those previously achieved with the BTE wEEG.

2.2 Primary endpoint

The primary endpoint is the diagnostic performance of the automated absence seizure detection algorithm using the investigational device data, measured by:

  • Sensitivity (Recall): The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.
  • Precision: the proportion of positive predictions that were actually correct when compared to the vEEG.
  • F1-score: a harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.
  • False Alarm Rate (FAR): The number of false positive detections per 24 hours of recording.

2.3 Secondary endpoints

Signal Quality Metrics: Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

Usability Scores: Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire).

Data Yield: The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

References

  1. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475-1499. doi:10.1111/epi.17236
  2. Jallon P, Latour P. Epidemiology of Idiopathic Generalized Epilepsies. Epilepsia. 2005;46(s9):10-14. doi:10.1111/j.1528-1167.2005.00309.x
  3. Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008;49(11):1838-1846. doi:10.1111/j.1528-1167.2008.01680.x
  4. Gruenbaum BF, Sandhu MRS, Bertasi RAO, et al. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia. 2021;62(5):1041-1056. doi:10.1111/epi.16862
  5. Callenbach PMC, Bouma PAD, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res. 2009;83(2-3):249-256. doi:10.1016/j.eplepsyres.2008.11.011
  6. Swinnen L, Chatzichristos C, Jansen K, et al. Accurate detection of typical absence seizures in adults and children using a two-channel electroencephalographic wearable behind the ears. Epilepsia. 2021;62(11):2741-2752. doi:10.1111/epi.17061
  7. Pizarro J, O'Sullivan S, Walker MC. How accurately do adult patients report their absence seizures? Epilepsia Open. Published online March 28, 2023:epi4.12689. doi:10.1002/epi4.12689
  8. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat Commun. 2018;9(1):88. doi:10.1038/s41467-017-02577-y
  9. Macea J, Chatzichristos C, Bhagubai M, De Vos M, Van Paesschen W. Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy. Epilepsia. 2025;66(7):2295-2306. doi:10.1111/epi.18384

Studietype

Observationeel

Inschrijving (Geschat)

25

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adults and children with idiopathic generalized epilepsy syndromes and typical absence seizures.

Beschrijving

Inclusion Criteria:

  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. At least 18 years of age at the time of signing the ICF or at least 6 years of age at the time their parents/legal representatives sign the caregiver's IFC and the minor participants sign the age-appropriate IFC.
  3. Confirmed diagnosis of the following idiopathic generalized epilepsy syndromes: CAE, JAE, or JME.
  4. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some Intra-Uterine Devices (IUDs), true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the investigation treatment(s)) or commitment to a vasectomised partner.
  5. Language: Subject and/or legal guardian must be able to understand the study instructions and the Informed Consent documents. These will be available in English and Dutch.

Exclusion Criteria:

  1. Patient has a history of other generalized epilepsy syndromes, such as Lennox-Gastaut.
  2. Anatomical Constraints: Anatomical abnormalities of the outer ear or ear canal that prevent the proper fit of the earEEG device.
  3. Participation in another clinical trial with an investigational drug or device that would interfere with the endpoints of this study.
  4. Female who is pregnant, breastfeeding, or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: CASE_ONLY
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Absence patients

Adults and children with idiopathic generalized epilepsy syndromes, i.e., Childhood Absence Epilepsy, Juvenile Absence Epilepsy, and Juvenile Myoclonic Epilepsy, with active disease and having typical absences.

Prospective, single-center, open-label, comparative diagnostic accuracy study. Study participants will be contacted during the screening phase based on the scheduled admission for 24-hour vEEG in the epilepsy monitoring units of UZ Leuven. After screening and signing the IFC, they will be asked to come to the hospital for ear-mold imprinting. These prints will serve as the basis for customizing the headset. The study will employ a hybrid design, consisting of two phases:

Phase A (In-Hospital Validation: participants will wear the IMD simultaneously with the standard 10-20 scalp EEG montage. This provides the ground truth labels for validation.

Phase B (At home): participants will wear the device at least once a week for 3 weeks to assess real-world usability

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sensitivity (Recall)
Tijdsspanne: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
Precision
Tijdsspanne: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The proportion of positive predictions that were actually correct when compared to the vEEG.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
F1-score
Tijdsspanne: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
False Alarm Rate in 24 hours
Tijdsspanne: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The number of false positive detections per 24 hours of recording.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Signal quality
Tijdsspanne: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
Usability Scores
Tijdsspanne: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire).

3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
Data Yield
Tijdsspanne: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Lauranne Scheldeman, UZ Leuven

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

11 januari 2027

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

30 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • S72895

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

IPD-tijdsbestek voor delen

Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

IPD-toegangscriteria voor delen

It will be open access

IPD delen Ondersteunend informatietype

  • ANALYTIC_CODE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .